Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a phase II study: Propylene Glycol-Free Melphalan Conditioning for Autologous Stem Cell Transplantation for AL Amyloidosis.

[1]  J. Berk,et al.  Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study , 2022, American journal of hematology.

[2]  M. Boccadoro,et al.  Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines , 2021, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[3]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[4]  G. Doros,et al.  Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  S. Sarosiek,et al.  Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis , 2020, Leukemia.

[6]  D. Dingli,et al.  Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation , 2018, Bone Marrow Transplantation.

[7]  A. Dispenzieri,et al.  Systemic immunoglobulin light chain amyloidosis , 2018, Nature Reviews Disease Primers.

[8]  G. Doros,et al.  Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation , 2018, American journal of hematology.

[9]  P. Hari,et al.  Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective , 2018, Bone Marrow Transplantation.

[10]  D. Dingli,et al.  Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Bayliss,et al.  A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time , 2017, British journal of haematology.

[12]  G. Doros,et al.  The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution , 2017, Bone Marrow Transplantation.

[13]  P. Hari,et al.  A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  D. Seldin,et al.  Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. , 2015, Blood.

[15]  A. Foli,et al.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.

[16]  K. Finn,et al.  Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis , 2014, Bone Marrow Transplantation.

[17]  Z. Bhat,et al.  Severe Propylene Glycol Toxicity Secondary to Use of Anti-Epileptics , 2014, American journal of therapeutics.

[18]  J. McGuirk,et al.  Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation , 2014, Bone Marrow Transplantation.

[19]  G. Doros,et al.  Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement , 2014, Bone Marrow Transplantation.

[20]  M. Skinner,et al.  High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. , 2012, Blood.

[21]  M. Dimopoulos,et al.  New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Skinner,et al.  Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. , 2011, Blood.

[23]  M. Guglin,et al.  Melphalan‐Induced Supraventricular Tachycardia: Incidence and Risk Factors , 2011, Clinical cardiology.

[24]  D. Dingli,et al.  Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report , 2010, Leukemia & lymphoma.

[25]  M. Perazella,et al.  Reviews: Recognition, Treatment, and Prevention of Propylene Glycol Toxicity , 2007, Seminars in dialysis.

[26]  K. Wilson,et al.  Clinical Investigations in Critical CarePropylene Glycol Toxicity: A Severe Iatrogenic Illness in ICU Patients Receiving IV Benzodiazepines: A Case Series and Prospective, Observational Pilot Study , 2005 .

[27]  R. Falk,et al.  High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study , 2004, Annals of Internal Medicine.

[28]  J. Fish,et al.  Propylene Glycol‐Associated Renal Toxicity from Lorazepam Infusion , 2003, Pharmacotherapy.

[29]  M. Skinner,et al.  Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. , 2003, Kidney international.